Financial Comparison: JanOne (NASDAQ:JAN) versus Trevena (NASDAQ:TRVN)

JanOne (NASDAQ:JANGet Free Report) and Trevena (NASDAQ:TRVNGet Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares JanOne and Trevena’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
JanOne N/A 1.55% 0.45%
Trevena N/A -314.87% -71.98%

Analyst Recommendations

This is a breakdown of recent ratings for JanOne and Trevena, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
JanOne 0 0 0 0 N/A
Trevena 0 0 2 0 3.00

Trevena has a consensus target price of $5.50, indicating a potential upside of 848.28%. Given Trevena’s higher probable upside, analysts plainly believe Trevena is more favorable than JanOne.

Earnings & Valuation

This table compares JanOne and Trevena’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
JanOne $39.61 million 0.08 $10.99 million N/A N/A
Trevena $570,000.00 17.59 -$53.67 million ($2.80) -0.21

JanOne has higher revenue and earnings than Trevena.

Insider and Institutional Ownership

11.7% of JanOne shares are owned by institutional investors. Comparatively, 5.0% of Trevena shares are owned by institutional investors. 3.0% of JanOne shares are owned by insiders. Comparatively, 3.3% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

JanOne has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Trevena has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Summary

JanOne beats Trevena on 6 of the 10 factors compared between the two stocks.

About JanOne

(Get Free Report)

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.

About Trevena

(Get Free Report)

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Receive News & Ratings for JanOne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JanOne and related companies with MarketBeat.com's FREE daily email newsletter.